China Biologic Products, Inc. (NASDAQ: CBPO) ("China Biologic" or the "Company"), a fully integrated plasma-based biopharmaceutical company in China, on Feb 15 announced that the Company plans to release fourth quarter and Fiscal Year 2016 financial results on Thursday, February 23, 2017 after the market closes.
The Company's management will hold a conference call at 7:30 a.m. ET on Friday, February 24, 2017, which is 8:30 p.m., Beijing Time on February 24, 2017, to discuss fourth quarter and fiscal year 2016 results.
China Biologic is a plasma-based biopharmaceutical company in China. The Company's products are used as critical therapies during medical emergencies and for the prevention and treatment of life-threatening diseases and immune-deficiency related diseases. China Biologic is headquartered in Beijing and manufactures over 20 different dosages of plasma-based products through its majority-owned subsidiary, Shandong Taibang Biological Products Co., Ltd., and its wholly-owned subsidiary, Guizhou Taibang Biological Products Co., Ltd. The Company also has an equity investment in Xi'an Huitian Blood Products Co., Ltd. The Company sells its products to hospitals and inoculation centers, as well as distributors, in China
